The board of directors of SSY Group Limited announced that the National Medical Products Administration of China (the "NMPA") has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group's Cefalexin Capsules (0.25g and 0.125g). Cefalexin Capsule is mainly used in the treatment of infections of respiratory tract (including acute tonsillitis, angina, sinusitis, bronchitis and pneumonia), middle ear, urinary tract, skin and soft tissue which are caused by susceptible bacteria. In addition, the Board is also pleased to announce that the Group's Doxazonsin Mesylate has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

Doxazonsin Mesyrate is an antihypertensive drug, which is mainly used for patients with mild or moderate primary hypertension and with benign prostatic hyperplasia.